40
Participants
Start Date
May 8, 2024
Primary Completion Date
December 1, 2025
Study Completion Date
December 1, 2030
Camrelizumab
Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
Cisplatin
75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
Nab paclitaxel
260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
biopsy
cone biopsy + pelvic lymphadenectomy or Cervical biopsy + pelvic lymphadenectomy
RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Women's Hospital School Of Medicine Zhejiang University
OTHER
Third Military Medical University
OTHER
Beijing Friendship Hospital
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
Tianjin Medical University
OTHER
West China Second University Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
Qilu Hospital of Shandong University
OTHER
Gansu Cancer Hospital
OTHER
Zhejiang Cancer Hospital
OTHER
Shengjing Hospital
OTHER
Anhui Provincial Cancer Hospital
OTHER
Tongji Hospital
OTHER